Pilot Study of a Multicomponent Nurse Intervention to Reduce Delirium in Hospitalized Older Adults (MID-Nurse-P)

September 23, 2015 updated by: Pedro Abizanda, Complejo Hospitalario Universitario de Albacete

Pilot Study of a Multicomponent Nurse Intervention to Reduce the Incidence and Severity of Delirium in Hospitalized Older Adults: MID-Nurse-P

Objectives: To analyze if a multicomponent nurse-led intervention randomized clinical trial (MID-Nurse Study) is feasible (Pilot study), and can reduce the incidence, duration, and severity of delirium in hospitalized older adults in an AGU.

Design: Parallel-group Double-blind Randomized Clinical Trial (Pilot Study). Setting: AGU "Complejo Hospitalario Universitario from Albacete" (Albacete, Spain).

Participants: 50 patients ≥ 65 years hospitalized in the AGU (21 intervention group, 29 control group).

Interventions: After risk factor analysis, all participants in the intervention group (IG) received a daily multicomponent intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain) by the intervention nurses. The control group (CG) received usual care.

Measurements: Delirium presence was determined daily with the Confusion Assessment Method (CAM), and delirium severity with the Delirium Rating Scale-Revised-98 (DRS). Mortality, days of hospitalization, use of physical restraint measures, and use of drugs for delirium control (neuroleptics and benzodiacepines) were also recorded.

Study Overview

Status

Completed

Conditions

Detailed Description

Parallel-group, double blind (evaluation and analysis), randomized clinical trial (pilot study). The design was based on recommendations for conducting pilot studies (Thabane 2010).

The main objective of the MID-Nurse (Randomized Clinical Trial) was to analyze if a multicomponent nurse-led intervention reduces the incidence, duration, and severity of delirium in hospitalized older adults in an Acute Geriatric Unit (AGU).

Specific objectives and evaluating criteria of the MID-Nurse-P (Pilot Study) were:

  • Process: To determine the recruitment rate (criteria: at least 70% of the eligible patients can be recruited), the complete follow-up rate (criteria: at least 85% of the included participants complete the follow-up), and the adherence to intervention (criteria: at least 80% of the included participants receive every scheduled intervention).
  • Resources: To assess capacity of the team and process time to conduct the trial. Criteria: Less than 10% of the participants can´t complete the intervention program due to study team problems, and daily time employed per participant is not longer than 30 minutes.
  • Management: To analyze potential study personnel and data managing problems.
  • Scientific: To estimate the intervention effect and the variance.

In the first 24 hours from admission, all the following data were collected by the evaluation nurses, once the informed consent was signed, and randomization performed by the principal investigator, who did not take part in the rest of the data collection and clinical intervention: Demographic data, Charlson comorbidity index, mean clinical diagnosis for admission, usually consumed drugs before admission, Barthel index, Holden´s FAC instrument, Pfeiffer´s Short Portable Mental Status Questionnaire, Reisberg´s Global Deterioration Scale, Dowton scale, pain with the visual analogical scale, and pressure ulcers risk with the Braden scale. Vital signs were determined on admission, including blood pressure, heart rate, temperature, hydration level, and oxygen saturation. Medical or nurse procedures were recorded, including bladder catheterization, nasogastric tube placement, venous or arterial access, blood sample acquisition, and other invasive procedures.

Blood sample was collected, and haemoglobin, leukocyte and neutrophil count, reactive C protein, sedimentation rate, glucose, urea, sodium, potassium, albumin, total proteins, cholesterol, thyroid stimulating hormone, transferrin, ferritin, total iron, folic acid, and B12 vitamin, were recorded.

After patient enrollment, all the patients received daily an evaluation of the Confusion Assessment Method scale (CAM) (Inouye 1990) by the evaluation nurses, in the afternoon. Prevalence of delirium throughout the follow-up was described, prevalence excluding the first day (to avoid bias of patients that were admitted with confusion), and incidence of delirium (new case across the follow-up, one patient could have more than 1 incident delirium). Number of days with delirium were also registered, and mean number of days with delirium was calculated for both groups.

In the case that the CAM was positive for delirium, patients also were evaluated with the Delirium Rating Scale-Revised-98 (DRS-R-98) (de Rooij 2006) to determine delirium severity. Total delirium severity was calculated by adding the severity of delirium during all days of hospitalization, and mean severity per day was calculated dividing the global severity per number of days with delirium.

Main outcome variables were the presence of delirium throughout the follow-up (dichotomic variable, yes/no), number of days with delirium during hospitalization (continuous variable), and total delirium severity (sum of DRS-R-98 during the complete follow-up).

Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. Participants in the control group received usual medical and nurse care during all the hospitalization process. The intervention was carried out exclusively by the "intervention nurses", and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Albacete, Spain, 02006
        • Complejo Hospitalario Universitario de Albacete

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

61 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with an age equal or older than 65 years
  • Hospitalized at the Acute Geriatric Unit of the "Complejo Hospitalario Universitario of Albacete"
  • Valid signed informed consent by the patient or legal representative.

Exclusion Criteria:

  • Agonic situation
  • Non-Spanish speaking
  • Severe cognitive decline (Reisberg´s Global Deterioration Scale = 7)
  • Patients sharing the same room with a previously included participant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control Group
Usual care
Experimental: Intervention Group
Multicomponent nurse-led intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain)
Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the "intervention nurses", and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Delirium incidence (% participants)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Delirium incidence during hospitalization (% participants)
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean daily delirium severity (mean score Delirium Rating Scale-Revised-98)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Mean delirium severity per day with delirium (mean score Delirium Rating Scale-Revised-98)
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Mortality (% of participants)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Mortality (% of participants)
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Length of stay (days)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Length of hospitalization time (days)
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Restraint measures (number of participants with these measures)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Use of restraint measures for delirium control (number of participants with these measures)
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Drugs for delirium (% of participants using neuroleptics or benzodiazepines)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Use of drugs (neuroleptics or benzodiazepines) for delirium control (% of participants)
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Delirium prevalence (% of participants)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Delirium prevalence during hospitalization (% of participants)
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Delirium severity (sum of total Delirium Rating Scale-Revised-98 socres during hospitalization)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Delirium severity during hospitalization (sum of total Delirium Rating Scale-Revised-98 socres during hospitalization)
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Recruitment rate (% of patients)
Time Frame: Up to five months
% of the eligible patients recruited
Up to five months
Complete follow-up rate (% of participants)
Time Frame: Up to five months
% of the included participants completing the follow-up
Up to five months
Adherence to intervention (% of participants)
Time Frame: Up to five months
% of included participants receiving every scheduled intervention
Up to five months
Capacity of the team (% of participants)
Time Frame: Up to five months
% of participants that can´t complete the intervention program due to study team problems
Up to five months
Process time (time in minutes)
Time Frame: Up to five months
Daily time employed per participant for delivering the intervention
Up to five months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pedro Abizanda, MD,PhD, Complejo Hospitalario Universitario de Albacete (SESCAM)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2013

Primary Completion (Actual)

February 1, 2014

Study Completion (Actual)

February 1, 2014

Study Registration Dates

First Submitted

July 28, 2015

First Submitted That Met QC Criteria

September 23, 2015

First Posted (Estimate)

September 24, 2015

Study Record Updates

Last Update Posted (Estimate)

September 24, 2015

Last Update Submitted That Met QC Criteria

September 23, 2015

Last Verified

September 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

Clinical Trials on Multicomponent nurse-led intervention

Subscribe